The intended audience for this activity are hematologic oncologists, hematologists, oncology advanced practice providers (NPs and PAs), oncology nurses, and other clinicians involved in the management of patients with CLL.
Upon completion of this activity, participants should be better able to:
- Review patient-specific criteria that determine eligibility for first-line and subsequent CLL therapies
- List the emerging combination regimens, including BTK inhibitors
- Discuss recent and new data supporting the role of BTK inhibitors in r/r CLL
- Integrate patient perspectives and priorities into comprehensive care-team management of CLL